Pre-made Roledumab benchmark antibody ( Whole mAb, anti-RHD therapeutic antibody, Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Roledumab biosimilar, Whole mAb, Anti-RHD Antibody: Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen.
| Products Name (INN Index) | Pre-Made Roledumab biosimilar, Whole mAb, Anti-RHD Antibody: Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI therapeutic antibody |
|---|---|
| INN Name | Roledumab |
| Target | RHD |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | LFB Biotechnologies |
| Conditions Approved | NA |
| Conditions Active | Haemolytic disease of newborn |
| Conditions Discontinued | NA |
| Development Tech | EMABling Platform |
| Previous Name | NA |
| Gm Offical Target Name | RHD |
| Package |
